1843 - 2027

London Health Sciences Centre – (IMvoke) A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients with High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

It seems we can’t find what you’re looking for. Perhaps searching can help.